WRIGHT HEALTH / RESEARCH IN MOTION
From oncology insight
to regenerative
peptide innovation.
Gene-therapy research. Regenerative peptide development.
For oncology, skin and deeper connective tissue.
01 / Our point of departure
ONCOLOGY → NEW POSSIBILITIESOne scientific origin.
Two paths forward.
We began with p53, the “guardian of the genome,” and the question of how to restore a tumor-suppression pathway disrupted in many cancers.
Today, Wright Health is advancing a p53 gene-therapy research program alongside regenerative peptide development for skin and deeper connective tissue. Different applications. Distinct evidence requirements. A shared ambition to translate research into clinical benefit.
The biology behind our origin / NIH MedlinePlus ↗Discover where the research is going
Computational design today. Laboratory evidence next.
02 / Our divisions
EXPLORE THE OPPORTUNITY
Skin &
Tissue.
Regenerative peptide development for skin and deeper connective tissue. Topical cosmetic formulations alongside an investigational oral BPC-157 pathway for deeper tissue repair/regeneration.
Oncology.
Designing a p53-encoding RNA/DNA expression system with targeted delivery and controllable expression as development objectives. Moving toward pre-clinical validation.
Scientific imagery is conceptual. Programs are in development.
03 / From insight to evidence
THE DEVELOPMENT APPROACHBetter questions.
Meaningful next steps.
Our experimental design connects p53 gene-therapy research with regenerative peptide development for skin and deeper connective tissue. Each program has its own route and evidence requirements.
Two programs. Specific design questions.
Use iterative bioinformatics, literature review and formulation design to define testable development plans.
ONCOLOGY / GENE THERAPY
Optimize the p53 coding sequence and RNA/DNA expression architecture alongside a delivery vehicle. Targeted delivery and controlled p53 expression are design objectives; the final format remains under evaluation.
SKIN & DEEPER CONNECTIVE TISSUE
Formulate identified peptides for topical cosmetic use. In parallel, develop an investigational oral BPC-157 formulation for evaluation in deeper tissue repair/regeneration, including tendon and ligament injuries.
Program-specific expression/delivery and formulation plans
Explore peptide development
01 — DESIGN
SKIN & TISSUE / PARALLEL DEVELOPMENT PATHWAYS04 / A tangible starting point
Start focused.
Build from evidence.
A peptide-containing facial moisturizer is our working starting point for skin care.
We are defining the candidate, formulation and performance questions that could support a differentiated product. Safety, stability and product-specific evidence come before a commercial decision.
In parallel, we plan to evaluate an oral BPC-157 formulation for deeper tissue repair/regeneration, including tendon and ligament injuries. This investigational therapeutic pathway requires a longer development program, including delivery, safety and efficacy studies.
Inside the product approachExplore the oral BPC-157 pathway
05 / The research behind the questions
Grounded in the literature.
Accountable to our own results.
Published studies help frame the opportunity. They do not establish the performance of a Wright Health candidate.
06 / Investment opportunity
Back the next
body of evidence.
Our proposed $8M staged financing supports peptide product development and early oncology validation. Each stage is intended to produce a clearer basis for the next decision.
Explore the investment opportunity